BlackRock, Inc. 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-29 3:26 pm Purchase |
2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
BLACKROCK INC BLK |
4,684,975 6.600% |
1,212,796 (+34.93%) |
Filing |
| 2023-02-01 4:54 pm Purchase |
2022-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
BLACKROCK INC BLK |
3,472,179 6.100% |
629,234 (+22.13%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
BLACKROCK INC BLK |
2,842,945 6.300% |
567,796 (+24.96%) |
Filing |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
BLACKROCK INC BLK |
2,275,149 5.600% |
2,275,149 (New Position) |
Filing |